283,679 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Castellan Group

Castellan Group purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 283,679 shares of the biopharmaceutical company’s stock, valued at approximately $8,539,000. TG Therapeutics accounts for approximately 3.7% of Castellan Group’s investment portfolio, making the stock its 3rd largest position. Castellan Group owned 0.18% of TG Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp boosted its holdings in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares during the period. Public Sector Pension Investment Board bought a new stake in shares of TG Therapeutics during the third quarter worth approximately $6,619,000. JPMorgan Chase & Co. boosted its holdings in shares of TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after acquiring an additional 270,286 shares during the period. Finally, PFM Health Sciences LP acquired a new stake in shares of TG Therapeutics in the third quarter valued at approximately $5,459,000. Institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Wednesday, January 15th. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, StockNews.com downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $40.67.

Insider Activity

In related news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.50% of the stock is owned by corporate insiders.

TG Therapeutics Stock Down 0.7 %

Shares of TGTX opened at $30.90 on Thursday. TG Therapeutics, Inc. has a 52 week low of $12.84 and a 52 week high of $36.84. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a fifty day moving average of $31.28 and a 200-day moving average of $27.21.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.